Aduhelm

(Aducanumab-avwa)

Aduhelm

Drug updated on 11/14/2023

Dosage FormInjection (intravenous; 170 mg/1.7 mL, 300 mg/3 mL)
Drug ClassAmyloid beta-directed antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of Alzheimer’s disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Aduhelm (aducanumab-avwa) Prescribing Information.2023Biogen Inc., Cambridge, MA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Aducanumab for the treatment of Alzheimer's disease: a systematic review.2023Psychogeriatrics
Immunotherapies targeting amyloid and Tau protein in Alzheimer’s disease: should we move away from diseases and focus on biological targets? A systematic review and expert opinion. 2023Neurology and Therapy
Comparative study of safety and efficacy of angiotensin-receptor blockers and anti amyloid-ß monoclonal antibodies for the treatment of alzheimer’s disease: a systematic review. 2023Cureus
Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer’s disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis. 2023Ageing Research Reviews
Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer’s disease: a systematic review and network meta-analysis.2022Ageing Research Reviews
Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review.2022JAMA Neurology
High-clearance anti-amyloid immunotherapies in Alzheimer’s disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. 2022Revue Neurologique
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review.2021Ageing Research Reviews
Aducanumab for Alzheimer’s disease: effectiveness and value.2021ICER
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease.2021Ageing Research Reviews